Results 1 to 10 of about 3,123 (163)

Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections [PDF]

Antibiotics
Introduction: Suppressive antibiotic therapy (SAT) is a therapeutic alternative for complex infections where a cure is considered unlikely or impossible. SAT involves the prolonged, often indefinite, administration of antibiotics, typically given orally,
Rosa Escudero-Sanchez, Laura Morata, Luis Buzón, Sofia de la Villa, Alicia Rico, María José Nuñez Orantos, Laura Guio Carrion, María Tasias Pitarch, Jose Luis del Pozo, José M. Barbero, Joan Gómez-Junyent, María José García Pais, Pablo Bachiller Luque, Francisco Javier Martínez Marcos, Javier Cobo, GEIO (Spanish Group for Osteoarticular Infections)   +15 more
doaj   +3 more sources

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience [PDF]

Antibiotics, 2023
Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment.
Dario Cattaneo, Marta Fusi, Marta Colaneri, Chiara Fusetti, Camilla Genovese, Riccardo Giorgi, Maddalena Matone, Stefania Merli, Francesco Petri, Andrea Gori   +9 more
doaj   +2 more sources

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium [PDF]

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide antibiotic that shows potent activity against Gram-positive bacteria. It circumvents vanB-type glycopeptide resistance mechanisms; however, data on the in vitro activity of dalbavancin for Enterococcus faecium (E ...
Robert E. Weber, Carola Fleige, Franziska Layer, Bernd Neumann, Michael Kresken, Guido Werner   +5 more
doaj   +2 more sources

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus [PDF]

Scientific Reports, 2021
Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and
Benjamin Jacob, Oliwia Makarewicz, Anita Hartung, Steffen Brodt, Eric Roehner, Georg Matziolis   +5 more
doaj   +2 more sources

Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis

International Journal of Infectious Diseases
Objectives: Due to its long half-life, dalbavancin offers benefits for long-duration treatments, especially osteoarticular and infective endocarditis (IE).
Antonio Perez-Landeiro, María Teresa Pérez-Rodríguez   +1 more
exaly   +3 more sources

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care

Antibiotics, 2020
Introduction: Dalbavancin is an antibiotic administered by intravenous infusion weekly or bi-weekly and is currently FDA-approved only for treatment of skin and soft-tissue infections. It has shown promise, but is not considered the standard of care, for
Sarah Schmalzle
exaly   +3 more sources

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti   +16 more
doaj   +1 more source

A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice

Antibiotics, 2022
The antibiotic dalbavancin is approved for intravenous treatment of adults with acute bacterial skin and skin structure infections. This study aimed to observe the use, effectiveness, and safety of dalbavancin in clinical practice in Germany.
Frank Hanses, Sebastian Dolff, Janina Trauth, Michael Seimetz, Stefan Hagel   +4 more
doaj   +1 more source

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection

BMC Infectious Diseases, 2023
Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment.
Anna Lange, Ulrica Thunberg, Bo Söderquist   +2 more
doaj   +1 more source

A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study

Journal of Global Antimicrobial Resistance, 2022
: Objective: To evaluate the cost-effectiveness of dalbavancin compared with standard of care (SoC) treatment as daptomycin or teicoplanin in patients with sternal wound infections (SWI).
Renato Pascale, Angelo Maccaro, Elisa Mikus, Maurizio Baldassarre, Beatrice Tazza, Fabio Esposito, Matteo Rinaldi, Elena Tenti, Simone Ambretti, Alberto Albertini, Pierluigi Viale, Maddalena Giannella, Michele Bartoletti   +12 more
doaj   +1 more source